My main academic and research trajectory focuses on pharmaceutical sciences, health economics, and evidence-based policy-making. My academic interests lie at the intersection of clinical pharmacology, health technology assessment (HTA), pharmacoepidemiology, and pharmaceutical policy. My research focuses on: a)Network meta-analysis and indirect comparisons of pharmaceuticals to support comparative effectiveness research. b)Health Technology Assessment (HTA) methodologies and their integration into national reimbursement frameworks. c)Pharmacoepidemiology and real-world data analysis, particularly using big data to evaluate prescribing patterns and treatment outcomes d)Reimbursement policies and access to innovative therapies, including biosimilars, orphan drugs, and gene therapies. e)Neuropharmacology, with a strong emphasis on systematic reviews and meta-analyses in dementia treatment. f)Personalized medicine and therapeutic drug monitoring, especially in vulnerable populations such as patients with renal insufficiency and g)Clinical trial design and evaluation, including protocol development and regulatory aspects. I have numerous publications in peer-reviewed international journals and presentations at leading scientific conferences. My work bridges scientific rigor with policy relevance, aiming to enhance the quality, efficiency, and equity of healthcare systems.